Kennondale Capital Management LLC purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 42,100 shares of the company's stock, valued at approximately $280,000. Kennondale Capital Management LLC owned about 0.08% of Stoke Therapeutics at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. GAMMA Investing LLC lifted its holdings in Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $113,000. Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after acquiring an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. purchased a new stake in shares of Stoke Therapeutics during the 4th quarter worth approximately $133,000.
Insider Activity at Stoke Therapeutics
In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total transaction of $64,904.13. Following the transaction, the insider owned 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 9.50% of the stock is currently owned by corporate insiders.
Stoke Therapeutics Stock Performance
STOK stock traded up $1.95 during midday trading on Tuesday, hitting $14.26. 541,307 shares of the stock were exchanged, compared to its average volume of 679,996. The stock's 50-day moving average price is $10.97 and its 200-day moving average price is $9.61. The stock has a market cap of $778.72 million, a price-to-earnings ratio of 18.05 and a beta of 1.14. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $16.15.
Analyst Ratings Changes
STOK has been the subject of a number of analyst reports. HC Wainwright decreased their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a research note on Wednesday, May 14th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a research note on Friday. They issued a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Cantor Fitzgerald upgraded Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday, May 14th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $25.80.
Check Out Our Latest Research Report on Stoke Therapeutics
Stoke Therapeutics Profile
(
Free Report)
Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.
Read More
Want to see what other hedge funds are holding STOK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Stoke Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stoke Therapeutics wasn't on the list.
While Stoke Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
